AI Engines For more Details: Perplexity Kagi Labs You
Muscle Relaxation: Mephenesin acts centrally on the nervous system to produce muscle relaxation by inhibiting nerve impulses or signals that cause muscles to contract. It helps alleviate muscle spasms, cramps, and stiffness, thereby promoting muscle relaxation and reducing pain associated with musculoskeletal conditions.
Pain Relief: By reducing muscle spasms and tension, mephenesin can help alleviate pain associated with conditions such as muscle strains, sprains, and other musculoskeletal injuries. It may be particularly beneficial for conditions where muscle tightness contributes to pain, such as tension headaches and back pain.
Adjunctive Therapy: Mephenesin is often used as an adjunctive therapy alongside other pain medications or treatments for musculoskeletal conditions. It may be prescribed in combination with analgesics (pain relievers) or physical therapy to enhance pain relief and improve mobility.
Skeletal Muscle Disorders: Mephenesin is indicated for various skeletal muscle disorders, including muscle spasticity due to neurological conditions such as multiple sclerosis or spinal cord injury, as well as musculoskeletal conditions like fibromyalgia and myofascial pain syndrome.
Sedative Effects: Mephenesin may have mild sedative effects due to its central nervous system depressant properties. Patients taking mephenesin should be cautious about activities requiring mental alertness, such as driving or operating machinery, especially when starting treatment or when dosage adjustments are made.
Adverse Effects: Common side effects of mephenesin may include drowsiness, dizziness, lightheadedness, sedation, gastrointestinal upset (such as nausea or vomiting), and allergic reactions in some individuals. Serious adverse effects are rare but may include severe allergic reactions, respiratory depression, and liver toxicity.
Contraindications: Mephenesin is contraindicated in individuals with known hypersensitivity to the medication and those with a history of liver disease or impairment. It should be used with caution in patients with respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD), as it may cause respiratory depression in high doses.
Drug Interactions: Mephenesin may potentiate the effects of other central nervous system depressants, including alcohol, sedatives, hypnotics, and opioids. Concurrent use of mephenesin with other medications that cause sedation or respiratory depression should be monitored closely to avoid adverse effects.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 1.8 | 0.3 | 5 |
| Allergic Rhinitis (Hay Fever) | 1.8 | 2.4 | -0.33 |
| Allergies | 3.8 | 2.8 | 0.36 |
| Allergy to milk products | 2.2 | 1.2 | 0.83 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 3.6 | 2.7 | 0.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 1.2 | 0.5 |
| Ankylosing spondylitis | 3.4 | 1 | 2.4 |
| Anorexia Nervosa | 1.1 | 1.3 | -0.18 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
| Asthma | 2.7 | 1.8 | 0.5 |
| Atherosclerosis | 2.2 | 0.4 | 4.5 |
| Atrial fibrillation | 1.9 | 1.8 | 0.06 |
| Autism | 4.9 | 5.2 | -0.06 |
| Autoimmune Disease | 1.2 | 0.5 | 1.4 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.5 | 2.5 | |
| Bipolar Disorder | 1.4 | 0.9 | 0.56 |
| Brain Trauma | 0.9 | 0.9 | 0 |
| Breast Cancer | 1.1 | 1.1 | |
| Cancer (General) | 0.6 | 1 | -0.67 |
| Carcinoma | 2.9 | 1.2 | 1.42 |
| Celiac Disease | 1.7 | 1.6 | 0.06 |
| Cerebral Palsy | 1.5 | 0.6 | 1.5 |
| Chronic Fatigue Syndrome | 3.1 | 2.4 | 0.29 |
| Chronic Kidney Disease | 1.6 | 0.7 | 1.29 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.3 | 1.2 | 0.92 |
| Chronic Urticaria (Hives) | 1.9 | 1.1 | 0.73 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 0.6 | 1.5 |
| Cognitive Function | 1.5 | 0.8 | 0.88 |
| Colorectal Cancer | 5.6 | 1.9 | 1.95 |
| Constipation | 1.3 | 1.3 | |
| Coronary artery disease | 2.2 | 1 | 1.2 |
| COVID-19 | 4.7 | 3.6 | 0.31 |
| Crohn's Disease | 4.9 | 2.4 | 1.04 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1.2 | 0.7 | 0.71 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.3 | 0.9 | 1.56 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 5.6 | 5.3 | 0.06 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 1.1 | 0.64 |
| Endometriosis | 2.3 | 1.4 | 0.64 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.1 | 1 | 2.1 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 0.5 | 1.9 | -2.8 |
| Functional constipation / chronic idiopathic constipation | 3.6 | 2.2 | 0.64 |
| gallstone disease (gsd) | 2.3 | 0.7 | 2.29 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 0.3 | 3.67 |
| Generalized anxiety disorder | 2.6 | 1.8 | 0.44 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.1 | 0.6 | 0.83 |
| Graves' disease | 1.5 | 2 | -0.33 |
| Gulf War Syndrome | 0.8 | 0.9 | -0.13 |
| Halitosis | 1.7 | 0.3 | 4.67 |
| Hashimoto's thyroiditis | 1.8 | 0.7 | 1.57 |
| Heart Failure | 3.2 | 0.7 | 3.57 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1 | 0.6 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.3 | 1.67 |
| hyperglycemia | 1.8 | 1 | 0.8 |
| Hyperlipidemia (High Blood Fats) | 0.7 | 0.3 | 1.33 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.5 | 2.2 | 0.14 |
| Hypothyroidism | 0.2 | 0.6 | -2 |
| Hypoxia | 2.3 | 0.3 | 6.67 |
| IgA nephropathy (IgAN) | 1.2 | 1.8 | -0.5 |
| Inflammatory Bowel Disease | 4.6 | 5.3 | -0.15 |
| Insomnia | 1.2 | 1.6 | -0.33 |
| Intelligence | 1.3 | 0.6 | 1.17 |
| Intracranial aneurysms | 0.9 | 0.6 | 0.5 |
| Irritable Bowel Syndrome | 4.8 | 3 | 0.6 |
| ischemic stroke | 2.3 | 0.9 | 1.56 |
| Liver Cirrhosis | 3.8 | 3.9 | -0.03 |
| Long COVID | 3.4 | 3.1 | 0.1 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.6 | 0.6 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.4 | 0.9 | 0.56 |
| ME/CFS with IBS | 0.6 | 1.1 | -0.83 |
| ME/CFS without IBS | 0.7 | 0.6 | 0.17 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 0.2 | 3.5 |
| Metabolic Syndrome | 4.5 | 3.8 | 0.18 |
| Mood Disorders | 5.4 | 4.7 | 0.15 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.7 | |
| Multiple Sclerosis | 4.2 | 2.6 | 0.62 |
| Multiple system atrophy (MSA) | 1.1 | 0.6 | 0.83 |
| myasthenia gravis | 0.9 | 0.2 | 3.5 |
| neuropathic pain | 0.8 | -0.8 | |
| Neuropathy (all types) | 0.4 | 0.6 | -0.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 2.1 | 0.71 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.6 | 1 |
| Obesity | 6.2 | 4.9 | 0.27 |
| obsessive-compulsive disorder | 2.7 | 2.2 | 0.23 |
| Osteoarthritis | 1.5 | 1.3 | 0.15 |
| Osteoporosis | 1.7 | 0.9 | 0.89 |
| pancreatic cancer | 0.8 | 0.3 | 1.67 |
| Parkinson's Disease | 4.9 | 3.6 | 0.36 |
| Polycystic ovary syndrome | 3.2 | 1.7 | 0.88 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.6 | 0.6 | |
| primary biliary cholangitis | 0.6 | 1.1 | -0.83 |
| Primary sclerosing cholangitis | 2 | 1 | 1 |
| Psoriasis | 2.9 | 1.5 | 0.93 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.9 | 2.1 | 1.33 |
| Rosacea | 0.6 | 0.2 | 2 |
| Schizophrenia | 3.5 | 1.8 | 0.94 |
| scoliosis | 0.9 | 0.3 | 2 |
| Sjögren syndrome | 1.8 | 0.7 | 1.57 |
| Sleep Apnea | 1.2 | 0.9 | 0.33 |
| Slow gastric motility / Gastroparesis | 1.4 | 0.3 | 3.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.3 | 6.33 |
| Stress / posttraumatic stress disorder | 1.8 | 1.5 | 0.2 |
| Systemic Lupus Erythematosus | 2.6 | 0.6 | 3.33 |
| Tic Disorder | 0.7 | 1.2 | -0.71 |
| Tourette syndrome | 0.4 | 0.3 | 0.33 |
| Type 1 Diabetes | 3 | 2.3 | 0.3 |
| Type 2 Diabetes | 4.8 | 4.1 | 0.17 |
| Ulcerative colitis | 3.5 | 2.9 | 0.21 |
| Unhealthy Ageing | 2.5 | 0.7 | 2.57 |
| Vitiligo | 1.4 | 1.2 | 0.17 |
